exv10w1






Exhibit 10.1









EMPLOYMENT AGREEMENT




EMPLOYMENT AGREEMENT (“Agreement”), entered into as of November 7, 2011 (the “Effective
Date”), by and between Impax Laboratories, Inc., a Delaware corporation (the “Company”), and Carole
Ben-Maimon (the “Executive”).



WITNESSETH:




WHEREAS, the Executive possesses unique personal knowledge, experience and expertise;



WHEREAS, the parties have each signed a letter for an offer of employment dated August 18,
2011 (“Former Offer”);



WHEREAS, the parties wish that this Agreement supersede and completely replace the Former
Offer;



WHEREAS, the Company desires to employ the Executive, and the Executive desires to be employed
by the Company, upon the terms and subject to the conditions set forth in the Agreement; and



WHEREAS, effective as of the Effective Date, the Company and the Executive desire to enter
into the Agreement as to the terms and conditions of the Executive’s employment with the Company.



NOW, THEREFORE, in consideration of the covenants and agreements hereinafter set forth and
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:



1. EMPLOYMENT AND DUTIES




1.1 Term of Employment. The Executive’s initial term of employment commenced on
September 6, 2011 (the “Hire Date”) and shall continue until December 31, 2012 (the “Initial
Term”), unless further extended or earlier terminated as provided in the Agreement. The Agreement
will automatically be renewed for single one-year periods unless written notice of non-renewal is
provided by either party at least 90 days prior to the end of the Initial Term or the successive
one-year period then in effect or unless earlier terminated as provided in the Agreement. Neither
non-renewal of the Agreement for additional periods after December 31, 2012, nor expiration of the
Agreement as a result of such non-renewal, shall, by itself, result in termination of Executive’s
employment. The period of time between the Hire Date and the termination of the Executive’s
employment under the Agreement or the expiration of the Agreement, whichever is earlier, shall be
referred to herein as the “Term.”


 


 









 





1.2 General.



1.2.1 During the Term, the Executive shall have the title of President Generic Products
Division (Global Pharmaceuticals) for the Company and shall have general supervision of the
Company’s generic business unit and such other authorities, duties and responsibilities as
may from time to time be delegated to her by the Chief Executive Officer of the Company. The
Executive shall faithfully and diligently discharge her duties hereunder and use her best efforts
to implement the policies established by the Board of Directors of the Company (the “Board”) from
time to time. During the Term, the Executive shall report to the Chief Executive Officer.



1.2.2 The Executive shall devote all of her business time, attention, knowledge and skills
faithfully, diligently and to the best of her ability, in furtherance of the business and
activities of the Company; provided, however, that nothing in the Agreement shall
preclude the Executive from devoting reasonable periods of time required for:



(i) serving as a director or member of a committee of up to three (3) organizations or
corporations that do not, in the good faith determination of the Board, compete with the Company or
otherwise create, or could create, in the good faith determination of the Board, a conflict of
interest with the business of the Company;



(ii) delivering lectures, fulfilling speaking engagements, and any writing or publication
relating to her area of expertise; provided, however, that any fees, royalties or
honorariums received therefrom shall be promptly turned over to the Company;



(iii) engaging in professional organization and program activities;



(iv) managing her personal passive investments and affairs; and



(v) participating in charitable or community affairs;



provided that such activities do not materially, individually or in the aggregate, interfere with
the due performance of her duties and responsibilities under the Agreement or create a conflict of
interest with the business of the Company, as determined in good faith by the Board.




1.3 Reimbursement of Expenses. During the Term, the Company shall pay the reasonable
expenses incurred by the Executive in the performance of her duties hereunder, including, without
limitation, those incurred in connection with business related travel or entertainment, or, if such
expenses are paid directly by the Executive, the Company shall promptly reimburse her for such
payments, provided that the Executive properly accounts for such expenses in accordance with the
Company’s business expense reimbursement policy. To the extent any such reimbursements (and any
other reimbursements of costs and expenses provided for herein) are includable in the Executive’s
gross income for Federal income tax purposes, all such reimbursements shall be made no later than
March 15 of the calendar year next following the calendar year in which the expenses to be
reimbursed are incurred.


 


-2-









 





2. COMPENSATION




2.1 Base Salary. During the Term, the Executive shall be entitled to receive a base
salary at the annual rate of $470,000.00, subject to increase or decrease, as determined by the
Board or its Compensation Committee from time to time in its discretion, payable in accordance with
the payroll practices of the Company (the “Base Salary”).



2.2 Incentive Bonuses. In addition to the Base Salary, during the Term the Executive
shall participate in the Company’s management bonus program whereby the Executive will be eligible
to receive an annual cash incentive bonus based upon a percentage of the Base Salary and attainment
of goals established in writing by the Board or its Compensation Committee at the beginning of each
year (together with the one-time cash payment referred to in the last sentence of the Section 2.2,
the “Incentive Bonus”) for each completed calendar year (subject to Section 5.4 hereof) of service
with the Company. Such bonus shall be paid within 2-1/2 months following the end of the calendar
year to which it relates. The Executive’s potential bonus for 2011 (targeted at 60% of the Base
Salary and potentially up to 90% of the Base Salary depending upon the achievement of certain
business and individual objectives and criteria) will be prorated based on the number of days that
have elapsed between the Hire Date and December 31, 2011. In addition, the Company shall pay the
Executive a one-time cash payment for 2011, concurrent with the timing of any bonus payments for
2011, in the amount of the difference between the prorated bonus amount the Executive actually
receives and the amount that she would have been eligible to receive, had she been employed with
the Company on July 1, 2011.



2.3 Options and Stock Awards. During the Term, the Executive shall be eligible to
receive grants of stock options and restricted stock in such amounts and subject to such terms as
determined by the Compensation Committee in its sole discretion.



2.4 Prior Options and Stock Awards. Executive acknowledges and agrees that the
Company has awarded her: (i) an option to purchase 75,000 shares of the Company’s common stock,
and (ii) 24,000 shares of Restricted Stock, in each case subject to the Company’s normal vesting
schedule of 25% per year starting on the first anniversary of the grant, so long as the Executive
remains employed by the Company.



2.5 Hiring Bonus. The Company shall pay the Executive a one-time hiring bonus of
$75,000.00, less applicable taxes and other required withholdings (“Hiring Bonus”). Executive
acknowledges and agrees that she has received one-half the Hiring Bonus in the gross amount of
$37,500, less standard deductions and withholdings. The second half of the Hiring Bonus in the
gross amount of $37,500.00, less standard deductions and withholdings shall be paid on the first
payroll date following the first year anniversary of the Hire Date; provided,
however, if within one (1) year of the Hire Date the Executive voluntarily terminates her
employment without Good Reason or the Company terminates the Executive’s employment for Cause (as
such terms are defined below), then the Executive shall repay the Company, within thirty (30) days
after the Company’s demand therefore, the full amount of the Hiring Bonus received, and if within
the second year following the Hire Date the Executive voluntarily terminates her employment without
Good Reason or the Company terminates the Executive’s employment for Cause (as such terms are
defined below), then the Executive shall repay the Company, within thirty (30) days after the
Company’s demand therefore, one-half of the amount of the Hiring Bonus received.


 


-3-









 





2.6 Additional Compensation. During the Term, in addition to the foregoing, the
Executive shall be eligible to receive such other compensation as may from time to time be awarded
her by either the Board or the Compensation Committee in its sole discretion.



3. PLACE OF PERFORMANCE




In connection with her employment by the Company, the Executive shall be based at the
Company’s offices in Chalfont, Pennsylvania.



4. EMPLOYEE BENEFITS




During the Term, the Executive shall be entitled to paid time off generally made available to
executive personnel of the Company and to participate in and have the benefit of all group life,
disability, hospital, surgical and major medical insurance plans and programs and other employee
benefit plans and programs as generally are made available to executive personnel of the Company,
as such benefit plans or programs may be amended or terminated in the sole discretion of the Board
and with the concurrence of the Compensation Committee, from time to time. The Executive shall
accrue up to sixteen (16) days of paid time off each calendar year which will accrue on a weekly
basis (paid time off cannot be used until it is accrued).



5. TERMINATION OF EMPLOYMENT




5.1 General. The Executive’s employment under the Agreement may be terminated without
any breach of the Agreement only on the following circumstances:



5.1.1 Death. The Executive’s employment under the Agreement shall terminate upon her
death.



5.1.2 Disability. If the Executive suffers a Disability (as defined below), the
Company may terminate the Executive’s employment under the Agreement upon 30 days prior written
notice; provided that the Executive has not returned to full time performance of her duties during
such 30-day period. For purposes of the Agreement, “Disability” shall mean the Executive’s
inability to perform her duties and responsibilities hereunder, with or without reasonable
accommodation, due to any physical or mental illness or incapacity, which condition either (i) has
continued for a period of 180 days (including weekends and holidays) in any consecutive 365-day
period, or (ii) is projected by the Board in good faith after consulting with a doctor selected by
the Company and consented to by the Executive (or, in the event of the Executive’s incapacity, her
legal representative), such consent not to be unreasonably withheld, that the condition is likely
to continue for a period of at least six consecutive months from its commencement.


 


-4-









 





5.1.3 Good Reason. The Executive may terminate her employment under the Agreement for
Good Reason (as defined below) at any time on or prior to the 60th day after the occurrence of any
of the Good Reason events set forth in the following sentence. For purposes of the Agreement,
“Good Reason” shall mean the occurrence of any of the following events without the Executive’s
consent and which is not cured by the Company upon written notice by the Executive, such notice to
have been provided by the Executive within 30 days of any such event having occurred:



(i) any action or inaction by the Company constituting a material breach of the Agreement by
the Company;



(ii) a material diminution of the authorities, duties or responsibilities of the Executive set
forth in Section 1.2 above (other than temporarily while the Executive is physically or mentally
incapacitated and unable to properly perform such duties, as determined by the Board in good
faith);



(iii) the loss of any of the titles of the Executive with the Company set forth in Section 1.2
above;



(iv) a material reduction by the Company in the Base Salary or in any of the percentages of
the Base Salary payable as an Incentive Bonus, but, except in the case of a reduction following a
Change in Control (as defined below), not including (a) a reduction in the Base Salary or in any of
the percentages of the Base Salary payable as an Incentive Bonus which is consistent with the
reduction in the Base Salary or in any of the percentages of the Base Salary payable as an
Incentive Bonus imposed on all senior executives of the Company or (b) a reduction in the Base
Salary or in any of the percentages of the Base Salary payable as an Incentive Bonus based on the
results of peer benchmark data obtained by the Board and after approval of the Board;



(v) the relocation of the Executive to an office more than 50 miles from its current location;



(vi) the assignment to the Executive of duties or responsibilities that are materially
inconsistent with any of her duties and responsibilities set forth in Section 1.2 hereof;



(vii) a material change in the reporting structure set forth in Section 1.2.1 hereof; or



(viii) the failure of the Company to obtain the assumption in writing of its obligation to
perform the Agreement by any successor in connection with a sale or other disposition by the
Company of all or substantially all of the Company’s assets or businesses within 10 days after such
sale or other disposition.



5.1.4 Without Good Reason. The Executive may voluntarily terminate her employment
under the Agreement without Good Reason upon written notice by the Executive to the Company at
least 60 days prior to the effective date of such termination (which termination the Company may,
in its sole discretion, make effective earlier than the date set forth in the Notice of Termination
(as defined below)).


 


-5-









 





5.1.5 Cause. The Company may terminate the Executive’s employment under the Agreement
at any time for Cause (as defined below). For purposes of the Agreement, termination for “Cause”
shall mean termination of the Executive’s employment because of the occurrence of any of the
following as determined in good faith by the Board:



(i) the willful and continued failure by the Executive to substantially perform her
obligations under the Agreement (other than any such failure resulting from the Executive’s
incapacity due to a Disability); provided, however, that the Company shall have
provided the Executive with a Notice of Termination specifying such failure and the Executive
shall have been afforded at least 15 days within which to cure same;



(ii) the indictment of the Executive for, or her conviction of or plea of guilty or nolo
contendere to, a felony or any other crime involving moral turpitude or dishonesty;



(iii) the Executive’s willful misconduct in the performance of her duties hereunder (including
theft, fraud, embezzlement, and securities law violations or violation of the Company’s Code of
Conduct or other written policies); or



(iv) the Executive’s willful misconduct other than in the performance of her duties for the
Company (including theft, fraud, embezzlement, and securities law violations) that is actually or
potentially materially injurious to the Company, monetarily or otherwise.



For purposes of the Section 5.1.5, no act or failure to act on the part of the Executive shall be
considered “willful,” unless done, or omitted to be done, without reasonable belief that her action
or omission was in, or not opposed to, the best interest of the Company (including its reputation).
Prior to any termination for Cause, the Company shall provide the Executive with a Notice of
Termination specifying the event constituting Cause and shall give the Executive the opportunity to
appear before the Board to present her views on the Cause event. If, after such hearing, the
majority of the full Board (excluding the Executive) does not support such termination, the Notice
of Termination shall be rescinded. After providing the notice in the foregoing sentence, the Board
may suspend the Executive with full pay and benefits until a final determination pursuant to the
Section has been made.




5.1.6 Without Cause. The Company may terminate the Executive’s employment under the
Agreement without Cause immediately upon written notice by the Company to the Executive, other than
for death or Disability.



5.2 Notice of Termination. Any termination of the Executive’s employment by the
Company or by the Executive (other than termination by reason of the Executive’s death) shall be
communicated by written Notice of Termination to the other party of the Agreement. For purposes of
the Agreement, a “Notice of Termination” shall mean a written notice which shall indicate the
specific termination provision in the Agreement relied upon and shall set forth in reasonable
detail the facts and circumstances claimed to provide the basis for such termination.


 


-6-









 





5.3 Date of Termination. The “Date of Termination” shall mean (a) if the termination
is the result of the Executive’s death, the date of her death, (b) if the termination is pursuant
to Section 5.1.2 hereof, 30 days after the Notice of Termination is given (provided that the
Executive shall not have returned to the performance of her duties on a full-time basis during such
30-day period), (c) if the termination is pursuant to Section 5.1.5 or Section 5.1.3 hereof, the
date specified in the Notice of Termination after the expiration of any applicable cure period, (d)
if the termination is pursuant to Section 5.1.4 hereof, the date specified in the Notice of
Termination which shall be at least 60 days after the Notice of Termination is given, or such
earlier date as the Company shall determine in its sole discretion, and (e) if the termination is
pursuant to Section 5.1.6 hereof, the date on which the Notice of Termination is given.



5.4 Compensation Upon Termination.



5.4.1 Termination for Cause or without Good Reason. If the Executive’s employment
shall be terminated by the Company for Cause or by the Executive without Good Reason, then the
Executive shall receive from the Company: (a) any earned but unpaid portion of the Base Salary
through the Date of Termination, paid in accordance with the Company’s standard payroll practices;
(b) any Incentive Bonus earned but unpaid for a prior fiscal year, paid in accordance with Section
2.2; (c) reimbursement for any unreimbursed expenses properly incurred and paid in accordance with
Section 1.3 through the Date of Termination; (d) payment for any accrued but unused vacation time
in accordance with Company policy; (e) all stock options and restricted stock previously granted to
the Executive that have vested in accordance with the terms of such grants; and (f) such vested
accrued benefits, and other payments, if any, as to which the Executive (and her eligible
dependents) may be entitled under, and in accordance with the terms and conditions of, the employee
benefit arrangements, plans and programs of the Company as of the Date of Termination, other than
any severance pay plan (such amounts and benefits set forth in clauses (a) though (f) being
referred to hereinafter as the “Amounts and Benefits”), and the Company shall have no further
obligation with respect to the Agreement other than as provided in Sections 7.4, 8 and 9 hereof.
Any stock options and restricted stock previously granted to the Executive that have not vested in
accordance with the terms of their grants as of the Date of Termination shall be forfeited as of
the Date of Termination.



5.4.2 Termination without Cause or For Good Reason. If, prior to the expiration of
the Term, the Executive resigns from her employment hereunder for Good Reason or the Company
terminates the Executive’s employment hereunder without Cause (other than a termination by reason
of death or Disability), and Section 5.4.3 does not apply, then the Company shall pay or provide
the Executive the Amounts and Benefits and, subject to Section 5.4.8:



(i) Subject to Section 9.9.2, an amount equal to the sum of (x) the balance of the Base Salary
due under the Agreement or one and one half times the Base Salary as then in effect (without taking
into account any reduction therein that constitutes a basis for Good Reason), whichever is the
greater, plus (y) an amount equal to one and one half times the average of the Incentive Bonus the
Executive received from the Company for all fiscal years completed during the Term, with the
aggregate amount due paid in equal installments on the Company’s normal payroll dates for a period
of 12 months from the Date of Termination in accordance with the normal payroll practices of the
Company, with each such payment deemed to be a separate payment for the purposes of Code Section
409A (as defined below);


 


-7-









 





(ii) in the event such resignation or termination occurs following the Company’s first fiscal
quarter of any year, a pro rata portion of the Executive’s Incentive Bonus for the fiscal year in
which the Executive’s termination occurs based on actual results for such year (determined by
multiplying the amount of such Incentive Bonus which would be due for the full fiscal year, as
determined in good faith by the Board, by a fraction, the numerator of which is the number of days
during the fiscal year of termination that the Executive is employed by the Company and the
denominator of which is 365), paid in accordance with, and at the times specified in, Section 2.2
(“Pro Rata Bonus”); and



(iii) the
continuation of all benefits for 24 months from the Date of Termination.



In addition, subject to Section 5.4.8, the vesting of all unvested stock options and restricted
stock previously granted to the Executive shall be accelerated by 12 months, and any such stock
options, notwithstanding any provision to the contrary in the option or the plan pursuant to which
the option was granted, shall remain exercisable for a period of 12 months following the Date of
Termination.



5.4.3 Termination Following Change in Control. Anything contained herein to the
contrary notwithstanding, if the Executive resigns from her employment hereunder for Good Reason,
the Company terminates the Executive’s employment hereunder without Cause (other than a termination
by reason of death or Disability) within 60 days preceding or 12 months following a Change in
Control (as defined below), or the Term expires or is not renewed due to the Company’s delivery of
a notice of nonrenewal and the Executive’s employment is then terminated without Cause within 12
months following a Change in Control, then the Company shall pay or provide the Executive the
Amounts and Benefits and, subject to Section 5.4.8, a change-in-control payment as follows:



(i) subject to Section 9.9.2, an amount equal to the sum of (x) the balance of the Base Salary
due under the Agreement or two and one quarter times the Base Salary as then in effect (without
taking into account any reduction therein that constitutes a basis for Good Reason), whichever is
the greater, plus (y) an amount equal to two and one quarter times the average of the Incentive
Bonus the Executive received from the Company for all fiscal years completed during the Term, with
the aggregate amount due paid in equal installments on the Company’s normal payroll dates for a
period of 12 months from the Date of Termination in accordance with the normal payroll practices of
the Company, with each such payment deemed to be a separate payment for the purposes of Code
Section 409A (as defined below);



(ii) in the event such resignation or termination occurs following the Company’s first fiscal
quarter of any year, a Pro Rata Bonus; and



(iii) the continuation of all benefits for 24 months from the Date of Termination.



In addition, subject to Section 5.4.8, the vesting of all unvested stock options and restricted
stock previously granted to the Executive shall be accelerated to the Date of Termination, and any
such stock options, notwithstanding any provision to the contrary in the option or the plan
pursuant to which the option was granted, shall remain exercisable for a period of 12 months
following the Date of Termination.



 


-8-









 





5.4.4 For purposes of the Agreement, a “Change in Control” shall be deemed to occur upon any
of the following events, provided that such an event is a Change in Control Event within the
meaning of Code Section 409A (as defined below): (a) any “person” as such term is used in Sections
13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than
the Company, any trustee or other fiduciary holding securities under any employee benefit plan of
the Company, or any company owned, directly or indirectly,
by the stockholders of the Company in substantially the same proportions as their ownership of
the common stock), becoming the beneficial owner (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company’s then outstanding securities; (b) during any period of 12 consecutive
months, the individuals who, at the beginning of such period, constitute the Board, and any new
director whose election by the Board or nomination for election by the Company’s stockholders was
approved by a vote of at least two-thirds of the directors then still in office who either were
directors at the beginning of the 12-month period or whose election or nomination for election was
previously so approved, cease for any reason to constitute at least a majority of the Board; (c) a
merger or consolidation of the Company with any other corporation or other entity, other than a
merger or consolidation that would result in the voting securities of the Company outstanding
immediately prior thereto (and held by persons that are not affiliates of the acquirer) continuing
to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity) more than 50% of the combined voting power of the voting securities of the
Company or such surviving entity outstanding immediately after such merger or consolidation;
provided, however, that a merger or consolidation effected to implement a
recapitalization of the Company (or similar transaction) in which no person (other than those
covered by the exceptions in clause (a) of the Section 5.4.4) acquires more than 50% of the
combined voting power of the Company’s then outstanding securities shall not constitute a Change in
Control; or (d) the consummation of a sale or other disposition by the Company of all or
substantially all of the Company’s assets, including a liquidation, other than the sale or other
disposition of all or substantially all of the assets of the Company to a person or persons who
beneficially own, directly or indirectly, more than 50% of the combined voting power of the
outstanding voting securities of the Company immediately prior to the time of the sale or other
disposition.



5.4.5 Termination upon Death. In the event of the Executive’s death, the Company
shall pay or provide to the Executive’s estate: (i) the Amounts and Benefits and (ii) a Pro Rata
Bonus. In addition, (A) all of the then remaining unvested restricted stock previously granted to
the Executive shall immediately become vested on the Date of Termination and shall be distributed
to the Executive’s estate within 60 days of the Date of Termination and (B) the portion of the
unvested stock options previously granted to the Executive that are scheduled to vest in the
calendar year of the Executive’s death shall immediately become vested on the certification of the
Compensation Committee based on the achievement of the performance goals for such year, calculated
through the Date of Termination, and shall be distributed to the Executive’s estate 60 days after
the Date of Termination. After giving effect to the foregoing, any portion of the stock options
that remain unvested on the certification following the Executive’s death shall be forfeited.


 


-9-









 





5.4.6 Termination upon Disability. In the event the Company terminates the
Executive’s employment hereunder for reason of Disability, the Company shall pay or provide to the
Executive: (i) the Amounts and Benefits, (ii) a Pro Rata Bonus and (iii) medical benefits for six
months. In addition, subject to Section 5.4.8, (A) 50% of the unvested restricted stock previously
granted to the Executive shall immediately become vested on the Date of Termination and shall be
distributed to the Executive as provided in, and subject to, Sections 5.4.8 and 9.9.2 and (B) the
portion of the unvested stock options previously granted to the Executive that are
scheduled to vest in the calendar year the Date of Termination occurs shall immediately become
vested on the certification of the Compensation Committee based on the achievement of the
performance goals for such year, calculated through the Date of Termination, and shall be
distributed to the Executive as provided in, and subject to, Sections 5.4.8 and 9.9.2. After
giving effect to the foregoing, any portion of the restricted shares and stock options that remain
unvested on the certification following the Date of Termination shall be forfeited as of the Date
of Termination.



5.4.7 No Mitigation or Offset. The Executive shall not be required to mitigate the
amount of any payment provided for in the Section 5.4 by seeking other employment or otherwise, nor
shall the amount of any payment provided for in the Section 5.4 be reduced by any compensation
earned by the Executive as the result of employment by another employer or business or by profits
earned by the Executive from any other source at any time before and after the Date of Termination.



5.4.8 Release. Notwithstanding any provision to the contrary in the Agreement, the
Company’s obligation to pay or provide the Executive with the payments and benefits under Sections
5.4.2 and 5.4.3 (other than the Amounts and Benefits), and any distributions with respect to the
restricted stock and stock options under Sections 5.4.2, 5.4.3 and 5.4.6, shall be conditioned on
the Executive’s execution and failure to revoke a waiver and general release in a form generally
consistent with Exhibit A hereto (subject to such changes as may be necessary at the time of
execution in order to make such release enforceable) (the “Release”). The Company shall provide
the Release to the Executive within seven days following the applicable Date of Termination. In
order to receive the payments and benefits under Sections 5.4.2 and 5.4.3 (other than the Amounts
and Benefits) and the distributions with respect to the restricted stock and stock options under
Sections 5.4.2, 5.4.3 and 5.4.6, the Executive will be required to execute and deliver the Release
within 21 days after the date it is provided to her and not to revoke it within seven days
following such execution and delivery. Notwithstanding anything to the contrary contained herein,
(i) all payments delayed pursuant to the Section, except to the extent delayed pursuant to Section
9.9.2, shall be paid to the Executive in a lump sum on the first Company payroll date on or
following the 60th day after the Date of Termination, and any remaining payments due under the
Agreement shall be paid or provided in accordance with the normal payment dates specified for them
herein, with each such payment deemed to be a separate payment for the purposes of Code Section
409A (as defined below) and (ii) all distributions with respect to the restricted stock and stock
options delayed pursuant to the Section, except to the extent delayed pursuant to Section 9.9.2,
shall be distributed to the Executive on the 60th day after the Date of Termination.


 


-10-









 





6. INSURABILITY; RIGHT TO INSURE




The Company shall have the right to maintain key man life insurance in its own name covering
the Executive’s life in an amount of up to $50,000,000.00. The Executive shall fully cooperate in
the procuring of such insurance, including submitting to any required medical examination and by
completing, executing and delivering such applications and other instrument in writing as may be
reasonably required by any insurance company to which application for insurance may be made by the
Company.



7. CONFIDENTIALITY; NON-SOLICITATION; NON-DISPARAGEMENT; COOPERATION




7.1 Confidential Information. The Company and the Executive acknowledge that the
services to be performed by the Executive under the Agreement are unique and extraordinary and, as
a result of such employment, the Executive shall be in possession of Confidential Information (as
defined below) relating to the business practices of the Company and its subsidiaries and
affiliates (collectively, the “Company Group”). The term “Confidential Information” shall mean any
and all information (oral and written) relating to the Company Group, or any of their respective
activities, or of the clients, customers or business practices of the Company Group, other than
such information which (i) is generally available to the public or within the relevant trade or
industry, other than as the result of breach of the provisions of the Section 7.1, or (ii) the
Executive is required to disclose under any applicable laws, regulations or directives of any
government agency, tribunal or authority having jurisdiction in the matter or under subpoena or
other process of law. Confidential Information includes, but is not limited to, information that
the Executive creates, develops, derives, obtains, makes known, or learns about which has
commercial value in the business in which the Company Group is involved and which is treated by the
Company Group as confidential, such as trade secrets, ideas, processes, formulas, compounds,
compositions, research and clinical data, know-how, discoveries, developments, designs,
innovations, plans, strategies, pricing, costs, financial information, employee information,
forecasts and current and prospective customer and supplier lists. The Executive shall not, during
the Term or at any time thereafter, except as may be required in the course of the performance of
her duties hereunder (including pursuant to Section 7.5 below) and except with respect to any
litigation or arbitration involving the Agreement, including the enforcement hereof, directly or
indirectly, use, communicate, disclose or disseminate to any person, firm or corporation any
Confidential Information acquired by the Executive during, or as a result of, her employment with
the Company, without the prior written consent of the Company. Without limiting the foregoing, the
Executive understands that the Executive shall be prohibited from misappropriating any trade secret
of the Company Group or of the clients or customers of the Company Group acquired by the Executive
during, or as a result of, her employment with the Company, at any time during or after the Term.


 


-11-









 





7.2 Return of Property. Upon the termination of the Executive’s employment for any
reason, all Company Group property that is in the possession of the Executive, including all
documents, records, drug formulations, notebooks, equipment, price lists, specifications, programs,
customer and prospective customer lists and other materials that contain Confidential Information
that are in the possession of the Executive, including all copies thereof, shall be promptly
returned to the Company. Anything to the contrary herein notwithstanding, the Executive shall be
entitled to retain (i) papers and other materials of a personal nature, including photographs,
correspondence, personal diaries, calendars and rolodexes, personal files and phone books, (ii)
information showing her compensation or relating to reimbursement of expenses, (iii) information
that she reasonably believes may be needed for tax purposes and (iv) copies of plans, programs and
agreements relating to her employment, or termination thereof, with the Company.



7.3 Prohibition on Use of Confidential Information to Solicit Customers and Prospects.
During the Executive’s employment, the Executive shall not engage in any other
employment or activity that might materially interfere with or be in direct competition with
the interests of the Company Group. Furthermore, the Executive shall not, except in the
furtherance of the Executive’s duties hereunder, directly or indirectly, individually or on behalf
of any other person, firm, corporation or other entity, (i) during the Term (except in the good
faith performance of her duties) and for a period of 24 months thereafter, solicit, aid or induce
any employee, representative or agent of the Company to leave such employment or retention or to
accept employment with or render services to or with any other person, firm, corporation or other
entity unaffiliated with the Company or hire or retain any such employee, representative or agent,
or take any action to materially assist or aid any other person, firm, corporation or other entity
in identifying, hiring or soliciting any such employee, representative or agent, (ii) during the
Term (except in the good faith performance of her duties) and for a period of 12 months thereafter,
use any Confidential Information or trade secrets of the Company Group to solicit, aid, or induce
(or attempt to do any of the foregoing), directly or indirectly, any customer or prospective
customer of the Company with whom the Executive in any way dealt at any time during the last two
years of her employment to purchase goods or services then sold by the Company from another person,
firm, corporation or other entity or assist or aid any other persons or entity in identifying or
soliciting any such customer or (iii) during the Term (except in the good faith performance of her
duties) and for a period of 24 months thereafter, use any Confidential Information or trade secrets
to interfere in any manner with the relationship of the Company and any of its vendors. An
employee, representative or agent shall be deemed covered by the Section while so employed or
retained by the Company and for six months thereafter. Anything to the contrary herein
notwithstanding, the following shall not be deemed a violation of the Section 7.3: (a) the
Executive’s responding to an unsolicited request for an employment reference regarding any former
employee of the Company from such former employee, or from a third party, by providing a reference
setting forth her personal views about such former employee; or (b) if an entity with which the
Executive is associated hires or engages any employee of the Company, if the Executive was not,
directly or indirectly, involved in hiring or identifying such person as a potential recruit or
assisting in the recruitment of such employee. For purposes hereof, the Executive shall be deemed
to have been involved “indirectly” in soliciting, hiring or identifying an employee only if the
Executive (x) directs a third party to solicit or hire the Employee, (y) identifies an employee to
a third party as a potential recruit or (z) aids, assists or participates with a third party in
soliciting or hiring an employee.


 


-12-









 





7.4 Non-Disparagement. At no time during or within five years after the Term shall
the Executive, directly or indirectly, disparage the Company Group or any of the Company Group’s
past or present employees, directors, products or services. The Company shall advise its senior
officers and the members of the Board (while serving in such capacities) not to disparage the
Executive during the period. Notwithstanding the foregoing, nothing in the Section 7.4 shall
prevent any person from making any truthful statement to the extent (i) necessary to rebut any
untrue public statements made about her or her; (ii) necessary with respect to any litigation,
arbitration or mediation involving the Agreement and the enforcement thereof; (iii) required by law
or by any court, arbitrator, mediator or administrative or legislative body (including any
committee thereof) with jurisdiction over such person; or (iv) made as good faith competitive
statements in the ordinary course of business.



7.5 Cooperation. Upon the receipt of reasonable notice from the Company (including
the Company’s outside counsel), the Executive shall, while employed by the Company and thereafter,
respond and provide information with regard to matters of which the Executive has knowledge as a
result of the Executive’s employment with the Company and will provide reasonable assistance to the
Company Group and its representatives in defense of any claims that may be made against the Company
Group (or any member thereof), and will provide reasonable assistance to the Company Group in the
prosecution of any claims that may be made by the Company Group (or any member thereof), to the
extent that such claims may relate to matters related to the Executive’s period of employment with
the Company (or any predecessors). Any request for such cooperation shall take into account the
Executive’s personal and business commitments. The Executive shall promptly inform the Company (to
the extent the Executive is legally permitted to do so) if the Executive is asked to assist in any
investigation of the Company Group (or any member thereof) or their actions, regardless of whether
a lawsuit or other proceeding has then been filed with respect to such investigation. If the
Executive is required to provide any services pursuant to the Section 7.5 following the Term, upon
presentation of appropriate documentation, the Company shall promptly reimburse the Executive for
reasonable out-of-pocket travel, lodging, communication and duplication expenses incurred in
connection with the performance of such services and in accordance with the Company’s expense
policy for its senior officers, and for reasonable legal fees to the extent the Board in good faith
believes that separate legal representation is reasonably required. The Executive’s entitlement to
reimbursement of such costs and expenses, including legal fees, pursuant to the Section 7.5, shall
in no way affect the Executive’s rights, if any, to be indemnified and/or advanced expenses in
accordance with the Company’s (or any of its subsidiaries’) corporate or other organizational
documents, any applicable insurance policy, and/or in accordance with the Agreement.



7.6 Remedies and Reformation. Without intending to limit the remedies available to
the Company, the Executive acknowledges that a breach of any of the covenants contained in the
Section 7 may result in material and irreparable injury to the Company, or its affiliates or
subsidiaries, for which there is no adequate remedy at law, that it will not be possible to measure
damages for such injuries precisely and that, in the event of such a breach or threat the Company
shall be entitled to a temporary restraining order and/or a preliminary or permanent injunction
restraining the Executive from engaging in activities prohibited by the Section 7 or such other
relief as may be required specifically to enforce any of the covenants in the Section 7. If for
any reason it is held that the restrictions under the Section 7 are not reasonable or that
consideration therefor is inadequate, such restrictions shall be interpreted or modified to include
as much of the duration and scope identified in the Section as will render such restrictions valid
and enforceable.


 


-13-









 





7.7 Violations. In the event of any violation of the provisions of the Section 7, the
Executive acknowledges and agrees that: (a) the post-termination restrictions contained in the
Section 7 shall be extended by a period of time equal to the period of such violation, it being the
intention of the parties hereto that the running of the applicable post-termination restriction
period shall be tolled during any period of such violation; (b) any severance payable which remains
unpaid or other benefits yet to be received under Section 5.4.2 or 5.4.3 shall be forfeited by the
Executive; and (c) any vested options not exercised as of the date of any violation of the
provisions of the Section 7 shall be forfeited.



8. INDEMNIFICATION; DIRECTORS’ AND OFFICERS’ LIABILITY INSURANCE




During the Term and thereafter, the Company shall indemnify and hold harmless the Executive
and her heirs and representatives as, and to the extent, provided in the Company’s by-laws. During
the Term and thereafter, the Company shall also cover Executive under the Company’s directors’ and
officers’ liability insurance on the same basis as it covers other senior executive officers and
directors of the Company.



9. MISCELLANEOUS




9.1 Notices. All notices or communications hereunder shall be in writing, addressed
as follows (or to such other address as either party may have furnished to the other in writing by
like notice):




	 	 	 	 	 

	 

	 	To the Company:
	 	Impax Laboratories, Inc.

121 New Britain Boulevard

Chalfont, PA 18914

Attn: Chairman, Compensation Committee







To the Executive, at the last address for the
Executive on the books of the Company.



All such notices shall be conclusively deemed to be received and shall be effective (i) if
sent by hand delivery, upon receipt, (ii) if sent by telecopy or facsimile transmission, upon
confirmation of receipt by the sender of such transmission, (iii) if sent by overnight courier, one
business day after being sent by overnight courier, or (iv) if sent by registered or certified
mail, postage prepaid, return receipt requested, on the fifth day after the day on which such
notice is mailed.



9.2 Severability. Each provision of the Agreement shall be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of the Agreement is held to
be prohibited by or invalid under applicable law, such provision will be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such provision or the
remaining provisions of the Agreement.


 


-14-









 





9.3 Binding Effect; Benefits. Executive may not delegate her duties or assign her
rights hereunder. No rights or obligations of the Company under the Agreement may be assigned or
transferred by the Company other than pursuant to a merger or consolidation in which the Company is
not the continuing entity, or a sale, liquidation or other disposition of all or substantially all
of the assets of the Company, provided that the assignee or transferee is the successor to all or
substantially all of the assets or businesses of the Company and assumes the liabilities,
obligations and duties of the Company under the Agreement, either contractually or by operation of
law. The Company further agrees that, in the event of any disposition of its business and assets
described in the preceding sentence, it shall use its best efforts to cause such assignee or
transferee expressly to assume the liabilities, obligations and duties of the Company hereunder.
For the purposes of the Agreement, the term “Company” shall include the Company and, subject to the
foregoing, any of its successors and assigns. The Agreement shall inure to the
benefit of, and be binding upon, the parties hereto and their respective heirs, legal
representatives, successors and permitted assigns.



9.4 Modification of Termination Benefits. In the event that RiskMetrics Group or a
proxy advisory firm of similar stature recommends that stockholders do not vote in favor of the
election of any of the Company’s Directors because of any provision of Sections 5 or 7 of the
Agreement, the Executive shall, upon request of the Company, enter into an amendment of the
Agreement modifying or eliminating such provision to the extent necessary to cause withdrawal of
such recommendation.



9.5 Entire Agreement. The Agreement, including the Exhibits hereto, represents the
entire agreement of the parties with respect to the subject matter hereof and shall supersede any
and all previous contracts, arrangements, proposed terms, or understandings between the Company and
the Executive, including without limitation the Former Offer. The Agreement (including any of the
Exhibits hereto) may be amended, modified or replaced at any time by mutual written agreement of
the parties hereto. In the case of any conflict between any express term of the Agreement and any
statement contained in any plan, program, arrangement, employment manual, memorandum or rule of
general applicability of the Company, the Agreement shall control.



9.6 Withholding. The payment of any amount pursuant to the Agreement shall be subject
to applicable withholding and payroll taxes, and such other deductions as may be required by
applicable law.



9.7 Governing Law. The Agreement and the performance of the parties hereunder shall
be governed by the internal laws (and not the law of conflicts) of the State of Delaware.



9.8 Arbitration. Any dispute or controversy, including but not limited to statutory
discrimination claims and claims involving a class, arising under or in connection with the
Agreement or the Executive’s employment with the Company, other than injunctive relief under
Section 7.7 hereof, shall be settled exclusively by arbitration, conducted before a single
arbitrator in San Francisco, California (applying Delaware law) in accordance with the Commercial
Arbitration Rules and Procedures of the American Arbitration Association then in effect. The
decision of the arbitrator will be final and binding upon the parties hereto. Judgment may be
entered on the arbitrator’s award in any court having jurisdiction. The parties acknowledge and
agree that in connection with any such arbitration and regardless of outcome (a) each party shall
pay all its own costs and expenses, including without limitation its own legal fees and expenses,
and (b) joint expenses shall be borne equally among the parties. EACH PARTY WAIVES RIGHT TO TRIAL
BY JURY.


 


-15-









 





9.9 Section 409A of the Code.



9.9.1 It is intended that the provisions of the Agreement comply with Section 409A of the
Internal Revenue Code and the regulations and guidance promulgated thereunder (collectively “Code
Section 409A”), and all provisions of the Agreement shall be construed in a manner consistent with
the requirements for avoiding taxes or penalties under Code Section 409A. If any provision of the
Agreement (or of any award of compensation, including equity
compensation or benefits) would cause the Executive to incur any additional tax or interest
under Code Section 409A, the Company shall, upon the specific request of the Executive, use its
reasonable business efforts to in good faith reform such provision to comply with Code Section
409A; provided, that to the maximum extent practicable, the original intent and economic benefit to
the Executive and the Company of the applicable provision shall be maintained, but the Company
shall have no obligation to make any changes that could create any additional economic cost or loss
of benefit to the Company. The Company shall timely use its reasonable business efforts to amend
any plan or program in which the Executive participates to bring it in compliance with Code Section
409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any
failure to comply with Code Section 409A so long as it has acted in good faith with regard to
compliance therewith.



9.9.2 A termination of employment shall not be deemed to have occurred for purposes of any
provision of the Agreement providing for the payment of any amounts or benefits upon or following a
termination of employment unless such termination is also a “Separation from Service” within the
meaning of Code Section 409A and, for purposes of any such provision of the Agreement, references
to a “resignation,” “termination,” “termination of employment” or like terms shall mean Separation
from Service. If the Executive is deemed on the Date of Termination to be a “specified employee,”
within the meaning of that term under Section (a)(2)(B) of Code Section 409A (“Code Section
409(a)(2)(B)”)and using the identification methodology selected by the Company from time to time,
or if none, the default methodology, then with regard to any payment, the providing of any benefit
or any distribution of equity made subject to the Section 9.9.2, to the extent required to be
delayed in compliance with Code Section 409A(a)(2)(B), and any other payment, the provision of any
other benefit or any other distribution of equity that is required to be delayed in compliance with
Code Section 409A(a)(2)(B), such payment, benefit or distribution shall not be made or provided
prior to the earlier of (i) the expiration of the six-month period measured from the date of the
Executive’s Separation from Service or (ii) the date of the Executive’s death. On the first day of
the seventh month following the date of Executive’s Separation from Service or, if earlier, on the
date of her death, (x) all payments delayed pursuant to the Section 9.9.2 (whether they would have
otherwise been payable in a single sum or in installments in the absence of such delay) shall be
paid or reimbursed to the Executive in a lump sum, and any remaining payments and benefits due
under the Agreement shall be paid or provided in accordance with the normal payment dates


 


-16-









 







specified
for them herein and (y) all distributions of equity delayed pursuant to the Section 9.9.2  shall be
made to the Executive. In addition to the foregoing, to the extent required by Code Section
409A(a)(2)(B), prior to the occurrence of both a Disability termination as provided in Section
5.1.2 hereof and the Executive’s becoming “disabled” under Code Section 409A, the payment of any
compensation to the Executive under the Agreement shall be suspended for a period of six months
commencing at such time that the Executive shall be deemed to have had a Separation from Service
because either (A) a sick leave ceases to be a bona fide sick leave of absence, or (B) the
permitted time period for a sick leave of absence expires (an “SFS Disability”), without regard to
whether such SFS Disability actually results in a Disability termination. Promptly following the
expiration of such six-month period, all compensation suspended pursuant to the foregoing sentence
(whether it would have otherwise been payable in a single sum or in installments in the absence of
such suspension) shall be paid or reimbursed to the Executive in a lump sum. On any delayed
payment date under the Section 9.9.2, there shall
be paid to the Executive or, if the Executive has died, to her estate, in a single cash lump
sum together with the payment of such delayed payment, interest on the aggregate amount of such
delayed payment at the Delayed Payment Interest Rate (as defined below) computed from the date on
which such delayed payment otherwise would have been made to the Executive until the date paid.
For purposes of the foregoing, the “Delayed Payment Interest Rate” shall mean the short term
Applicable Federal Rate as of the business day immediately preceding the payment date for the
applicable delayed payment.



9.9.3 With regard to any provision herein that provides for reimbursement of costs and
expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to
reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another
benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided
during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind
benefits to be provided, in any other taxable year, provided that the foregoing clause (ii) shall
not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b)
of the Internal Revenue Code and the regulations and guidance promulgated thereunder solely because
such expenses are subject to a limit related to the period the arrangement is in effect and (iii)
such payments shall be made on or before the last day of the Executive’s taxable year following the
taxable year in which the expense was incurred.



9.10 Survival. Except as otherwise expressly set forth in the Agreement, upon the
expiration of the Term, the respective rights and obligations of the parties shall survive such
expiration to the extent necessary to carry out the intentions of the parties as embodied in the
Agreement. The Agreement shall continue in effect until there are no further rights or obligations
of the parties outstanding hereunder and shall not be terminated by either party without the
express prior written consent of both parties.



9.11 Counterparts. The Agreement may be executed in counterparts (including by
electronic transmission) which, when taken together, shall constitute one and the same agreement of
the parties.


 


-17-









 





9.12 Company Representations. The Company represents and warrants to the Executive
that (i) the execution, delivery and performance of the Agreement (and the agreements referred to
herein) by the Company has been fully and validly authorized by all necessary corporate action,
(ii) the officer signing the Agreement on behalf of the Company is duly authorized to do so, (iii)
the execution, delivery and performance of the Agreement does not violate any applicable law,
regulation, order, judgment or decree or any agreement, plan or corporate governance document to
which the Company is a party or by which it is bound and (iv) upon execution and delivery of the
Agreement by the Executive and the Company, it shall be a valid and binding obligation of the
Company enforceable against it in accordance with its terms, except to the extent that
enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the
enforcement of creditors’ rights generally.



[Signature Page Follows]



 


-18-









 






IN WITNESS WHEREOF, the Company has caused the Agreement to be duly executed and the Executive
has hereunto set her hand, as of the date first set forth above.



	 	 	 	 	 
	 	IMPAX LABORATORIES, INC.

 	 
	 	By:  	/s/ Larry Hsu
 	 
	 	 	Name:  	Larry Hsu 	 
	 	 	Title:  	President & CEO 	 
	 	 	 
	 	                /s/ Carole Ben-Maimon
 	 
	 	Carole Ben-Maimon 	 


 


-19-









 













EXHIBIT A




Form of General Release and Waiver




The General Release and Waiver (the “Release”) is entered into effective as of                     
_____, 20_____, by                      (the “Executive”) in favor of Impax Laboratories, Inc. (the “Company”).



1. Confirmation of Termination. The Executive’s employment with the Company is
terminated as of                     , 20_____ (the “Termination Date”). Except as set forth in the Employment
Agreement (as defined below), the Executive acknowledges that the Termination Date is the
termination date of her employment for purposes of participation in and coverage under all benefit
plans and programs sponsored by or through the Company. The Executive acknowledges and agrees that
the Company shall not have any obligation to rehire the Executive, nor shall the Company have any
obligation to consider her for employment, after the Termination Date. The Executive agrees that
she will not seek employment with the Company at any time in the future.



2. Resignation. Effective as of the Termination Date, the Executive hereby resigns as
an officer and director of the Company and any of its affiliates and from any such positions held
with any other entities at the direction or request of the Company or any of its affiliates. The
Executive agrees to promptly execute and deliver such other documents as the Company shall
reasonably request to evidence such resignations. In addition, the Executive hereby agrees and
acknowledges that the Termination Date shall be date of her termination from all other offices,
positions, trusteeships, committee memberships and fiduciary capacities held with, or on behalf of,
the Company or any of its affiliates.



3. Termination Benefits. Upon the Executive’s execution and delivery of the Release
and failure to revoke it within the time specified in Section 10 below, then, subject to Section 9
below, the Executive will be entitled to the payments and benefits (subject to taxes and all
applicable withholding requirements) set forth under Section [5.4.2] [5.4.3] of the Employment
Agreement effective as of April _____, 2011 between the Company and the Executive (the “Employment
Agreement”) and the distribution with respect to the restricted stock and stock options set forth
under Section [5.4.2] [5.4.3] [5.4.6] of the Employment Agreement (the “Termination Benefits”).
Notwithstanding anything herein to the contrary, the Amounts and Benefits (as defined in the
Employment Agreement) shall not be subject to the Executive’s execution of the Release. The
Executive acknowledges and agrees that the Termination Benefits exceed any payment, benefit, or
other thing of value to which the Executive might otherwise be entitled under any policy, plan or
procedure of the Company and/or any agreement between the Executive and the Company, except as
provided above.


 


A-1









 





4. General Release and Waiver. In consideration of the Termination Benefits, and for
other good and valuable consideration, receipt of which is hereby acknowledged, the Executive for
herself and for her heirs, executors, administrators, trustees, legal representatives
and assigns (collectively, the “Releasors”), hereby releases, remises, and acquits the Company
and its affiliates and all of their respective past, present and future parent entities,
subsidiaries, divisions, affiliates and related business entities, any of their successors and
assigns, assets, employee benefit plans or funds, and any of their respective past and/or present
directors, officers, fiduciaries, agents, trustees, administrators, managers, supervisors,
shareholders, investors, employees, legal representatives, agents, counsel and assigns, whether
acting on behalf of the Company or its affiliates or, in their individual capacities (collectively,
the “Releasees” and each a “Releasee”) from any and all claims, known or unknown, which the
Releasors have or may have against any Releasee arising on or prior to the date of the Release and
any and all liability which any such Releasee may have to the Releasors, whether denominated
claims, demands, causes of action, obligations, damages or liabilities arising from any and all
bases, however denominated, including but not limited to (a) any claim under the Age Discrimination
in Employment Act of 1967 including the Older Workers Benefits Protection Act, the Americans with
Disabilities Act of 1990, the Family and Medical Leave Act of 1993, Title VII of the Civil Rights
Act of 1964, the Civil Rights Act of 1991, Section 1981 of the Civil Rights Act of 1866, the Equal
Pay Act, the Lilly Ledbetter Fair Pay Act, the Immigration Reform and Control Act of 1986, the
Employee Retirement Income Security Act of 1974, (excluding claims for accrued, vested benefits
under any employee benefit or pension plan of the Company, subject to the terms and conditions of
such plan and applicable law), and the Sarbanes-Oxley Act of 2002, all as amended; (b) any claim
under the California Fair Employment and Housing Act and any other provision of the California
employment law, all as amended, the Pennsylvania Human Relations Act, and any other provision of
the Pennsylvania employment law as amended or any other similar state or local laws; (c) any claim
under any other Federal, state, or local law and any workers’ compensation or disability claims
under any such laws to the extent such claims are waivable; and (d) any claim for attorneys’ fees,
costs, disbursements and/or the like. The Release includes, without limitation, any and all claims
arising from or relating to the Executive’s employment relationship with Company and her service
relationship as an officer or director of the Company or any of its affiliates, or as a result of
the termination of such relationships. Notwithstanding any other provision of the Release, the
Release is not intended to interfere with the Executive’s right to file a charge with the Equal
Employment Opportunity Commission (“EEOC”) in connection with any claim she believes she may have
against any Releasee. However, by executing the Release, the Executive hereby waives the right to
recover in any proceeding the Executive may bring before the EEOC or any state human rights
commission or in any proceeding brought by the EEOC or any state human rights commission on the
Executive’s behalf. The Release is for any relief, no matter how denominated, including, but not
limited to, injunctive relief, wages, back pay, front pay, compensatory damages, punitive damages,
and attorneys’ fees. The Release shall not apply to (i) the obligation of the Company to provide
the Executive with the Amounts and Benefits and the Termination Benefits and any provision relating
thereto under the Employment Agreement; (ii) the Executive’s rights to indemnification from the
Company or rights to be covered under any applicable insurance policy with respect to any liability
the Executive incurred or might incur as an employee, officer or director of the Company including,
without limitation, the Executive’s rights under Section 8 of the Employment Agreement; or (iii)
any right the Executive may have to obtain contribution as permitted by law in the event of entry
of judgment against the Executive as a result of any act or failure to act for which the Executive,
on the one hand, and Company or any other Releasee, on the other hand, are jointly liable.


 


A-2









 





The Executive waives and relinquishes all rights and benefits afforded by Section 1542 of the
Civil Code of California, to the extent applicable, which provides as follows:




A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO
EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER
MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.



The Executive hereby acknowledges that the foregoing waiver is an essential and material term of
the Release.




5. Continuing Covenants. The Executive acknowledges and agrees that she remains
subject to the provisions of Section 7 of the Employment Agreement which shall remain in full force
and effect for the periods set forth therein.



6. No Admission. The Release does not constitute an admission of liability or
wrongdoing of any kind by the Company or any other Releasee. The Release is not intended, and
shall not be construed, as an admission that any Releasee has violated any federal, state or local
law (statutory or decisional), ordinance or regulation, breached any contract or committed any
wrong whatsoever against any Releasor.



7. Heirs and Assigns. The terms of the Release shall be binding upon and inure to the
benefit of the parties named herein and their respective successors and permitted assigns.



8. Miscellaneous. The Release will be construed and enforced in accordance with the
laws of the State of Delaware without regard to the principles of conflicts of law. If any
provision of the Release is held by a court of competent jurisdiction to be illegal, void or
unenforceable, such provision shall have no effect; however, the remaining provisions will be
enforced to the maximum extent possible. The parties acknowledge and agree that, except as
otherwise set forth herein, the Release constitutes the complete understanding between the parties
with regard to the matters set forth herein and, except as otherwise set forth herein, supersede
any and all agreements, understandings, and discussions, whether written or oral, between the
parties. No other promises or agreements are binding unless in writing and signed by each of the
parties after the Release Effective Date (as defined below). Should any provision of the Release
require interpretation or construction, it is agreed by the parties that the entity interpreting or
constructing the Release shall not apply a presumption against one party by reason of the rule of
construction that a document is to be construed more strictly against the party who prepared the
document.


 


A-3









 





9. Knowing and Voluntary Waiver. The Executive acknowledges that she: (a) has
carefully read the Release in its entirety; (b) has had an opportunity to consider it for at least
21 days; (c) is hereby advised by the Company in writing to consult with an attorney of her
choosing in connection with the Release; (d) fully understands the significance of all of the terms
and conditions of the Release and has discussed them with her independent legal counsel, or had a
reasonable opportunity to do so; (e) has had answered to her satisfaction any questions she has
asked with regard to the meaning and significance of any of the provisions of the Release and has
not relied on any statements or explanations made by any Releasee or their counsel; (f) understands
that she has seven days in which to revoke the Release (as described in Section 10)
after signing it and (g) is signing the Release voluntarily and of her own free will and
agrees to abide by all the terms and conditions contained herein.



10. Effective Time of Release. The Executive may accept the Release by signing it and
delivering it to the Company as provided in Section 9.1 of the Employment Agreement within 21 days
of her receipt hereof. After executing the Release, the Executive will have seven days (the
“Revocation Period”) to revoke the Release by indicating her desire to do so in writing delivered
to the Company in accordance with Section 9.1 of the Employment Agreement by no later than 5:00
p.m. EST on the seventh day following the date on which she executes and delivers the Agreement.
The effective date of the Agreement shall be the eighth day after the Executive executes and
delivers the Agreement (the “Release Effective Date”). If the last day of the Revocation Period
falls on a Saturday, Sunday or holiday, the last day of the Revocation Period will be deemed to be
the next business day. If the Executive does not execute the Release or exercises her right to
revoke hereunder, she shall forfeit her right to receive any of the Termination Benefits, and to
the extent such Termination Benefits have already been provided, the Executive agrees that she will
immediately reimburse the Company for the amounts of such payment.



IN WITNESS WHEREOF, the Executive has duly executed the Release as of the date first set forth
above.



	 	 	 	 	 

	 

	 	EXECUTIVE:	 	 
	 
	 	 	 	 
	 

	 	 

Name:
	 	 






 


A-4